Drug Eluting Cardiovascular Devices Market Size, Share, Trends, Growth Outlook

Drug Eluting Cardiovascular Devices Market is estimated to increase at a growth rate of 7.5% CAGR over the forecast period from 2024 to 2030.

The Drug Eluting Cardiovascular Devices Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Product (Drug-Eluting Stents, Bioabsorbable Stents, Drug-Eluting Balloons), By End-User (Hospitals, Clinics, Others).

An Introduction to Drug Eluting Cardiovascular Devices Market in 2024

The Drug Eluting Cardiovascular Devices market in 2024 serves the demand for implantable medical devices coated with pharmacological agents for the prevention of restenosis and thrombosis following endovascular interventions such as angioplasty and stent placement in patients with coronary artery disease (CAD) and peripheral artery disease (PAD). Drug-eluting cardiovascular devices include drug-eluting stents, drug-coated balloons, and drug-eluting vascular grafts, which release antiproliferative or antithrombotic drugs locally to inhibit neointimal hyperplasia and reduce the risk of restenosis and thrombosis in treated arteries. Market dynamics are driven by factors such as the increasing prevalence of cardiovascular diseases, advancements in device technology and drug formulations, and the demand for durable and effective treatment options for patients undergoing percutaneous coronary interventions (PCIs) and endovascular procedures. Collaboration between medical device manufacturers, interventional cardiologists, and regulatory agencies drives innovation and market expansion in drug-eluting cardiovascular devices, supporting improved clinical outcomes and long-term patency rates in patients with obstructive arterial lesions and coronary artery disease.

Drug Eluting Cardiovascular Devices Market Trend: Advancements in Drug Eluting Technology

A prominent trend in the Drug Eluting Cardiovascular Devices market is the continuous advancements in drug eluting technology. Innovations in polymer science, drug formulation, and coating techniques have led to the development of next-generation drug eluting stents, drug eluting balloons, and other cardiovascular devices. These advancements aim to improve drug delivery efficiency, enhance therapeutic efficacy, and reduce the risk of restenosis and thrombosis following interventional procedures. Additionally, efforts are underway to develop biodegradable and bioresorbable drug-eluting coatings that provide sustained drug release while minimizing long-term vessel inflammation and late adverse events. The evolution of drug eluting technology drives market growth and innovation in the Drug Eluting Cardiovascular Devices segment, offering promising solutions for the treatment of coronary artery disease and other cardiovascular conditions.

Drug Eluting Cardiovascular Devices Market Driver: Growing Prevalence of Cardiovascular Diseases

A key driver in the Drug Eluting Cardiovascular Devices market is the growing prevalence of cardiovascular diseases worldwide. Cardiovascular diseases, including coronary artery disease, peripheral artery disease, and cardiac arrhythmias, remain leading causes of morbidity and mortality globally. As the population ages and risk factors such as obesity, diabetes, and hypertension become more prevalent, the incidence of cardiovascular diseases continues to rise. Drug eluting cardiovascular devices, such as drug eluting stents and drug eluting balloons, play a crucial role in the management of these conditions by restoring blood flow to diseased vessels, reducing the risk of restenosis, and improving patient outcomes. The increasing burden of cardiovascular diseases drives demand for innovative drug eluting devices, supporting market growth in the Drug Eluting Cardiovascular Devices segment.

Drug Eluting Cardiovascular Devices Market Opportunity: Integration of Adjunctive Therapies and Drug Delivery Platforms

One potential opportunity in the Drug Eluting Cardiovascular Devices market lies in the integration of adjunctive therapies and drug delivery platforms to enhance treatment outcomes. Researchers and manufacturers are exploring the combination of drug eluting devices with adjunctive therapies such as antiplatelet agents, anticoagulants, and growth factors to optimize vascular healing, prevent thrombosis, and promote tissue regeneration. Additionally, the development of novel drug delivery platforms, such as drug eluting microparticles and nanoparticle-based carriers, offers opportunities to enhance drug release kinetics, target specific cell types, and minimize systemic side effects. By integrating adjunctive therapies and advanced drug delivery platforms into drug eluting cardiovascular devices, manufacturers can improve therapeutic efficacy, reduce adverse events, and address unmet clinical needs, thereby driving market differentiation and growth in this segment.

Drug Eluting Cardiovascular Devices Market Segmentation

By Product
Drug-Eluting Stents
Bioabsorbable Stents
Drug-Eluting Balloons
By End-User
Hospitals
Clinics
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Drug Eluting Cardiovascular Devices Market Companies

Abbott
B. Braun Melsungen AG
Biotronik
Boston Scientific Corp
Cook Medical
Cordis Corp
Medtronic
MicroPort Scientific Corp
Sahajanand Medical Technologies
Terumo Corp

 

 

Reasons to Buy the Drug Eluting Cardiovascular Devices Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Drug Eluting Cardiovascular Devices Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Drug Eluting Cardiovascular Devices Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

 

TABLE OF CONTENTS

1 Introduction to 2024 Drug Eluting Cardiovascular Devices Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Drug Eluting Cardiovascular Devices Market Size Outlook, $ Million, 2021 to 2030
3.2 Drug Eluting Cardiovascular Devices Market Outlook by Type, $ Million, 2021 to 2030
3.3 Drug Eluting Cardiovascular Devices Market Outlook by Product, $ Million, 2021 to 2030
3.4 Drug Eluting Cardiovascular Devices Market Outlook by Application, $ Million, 2021 to 2030
3.5 Drug Eluting Cardiovascular Devices Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Drug Eluting Cardiovascular Devices Market Industry
4.2 Key Market Trends in Drug Eluting Cardiovascular Devices Market Industry
4.3 Potential Opportunities in Drug Eluting Cardiovascular Devices Market Industry
4.4 Key Challenges in Drug Eluting Cardiovascular Devices Market Industry

5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Drug Eluting Cardiovascular Devices Market Share by Company (%), 2023
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Drug Eluting Cardiovascular Devices Market Outlook By Segments
7.1 Drug Eluting Cardiovascular Devices Market Outlook by Segments
By Product
Drug-Eluting Stents
Bioabsorbable Stents
Drug-Eluting Balloons
By End-User
Hospitals
Clinics
Others

8 North America Drug Eluting Cardiovascular Devices Market Analysis And Outlook To 2030
8.1 Introduction to North America Drug Eluting Cardiovascular Devices Markets in 2024
8.2 North America Drug Eluting Cardiovascular Devices Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Drug Eluting Cardiovascular Devices Market size Outlook by Segments, 2021-2030
By Product
Drug-Eluting Stents
Bioabsorbable Stents
Drug-Eluting Balloons
By End-User
Hospitals
Clinics
Others

9 Europe Drug Eluting Cardiovascular Devices Market Analysis And Outlook To 2030
9.1 Introduction to Europe Drug Eluting Cardiovascular Devices Markets in 2024
9.2 Europe Drug Eluting Cardiovascular Devices Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Drug Eluting Cardiovascular Devices Market Size Outlook By Segments, 2021-2030
By Product
Drug-Eluting Stents
Bioabsorbable Stents
Drug-Eluting Balloons
By End-User
Hospitals
Clinics
Others

10 Asia Pacific Drug Eluting Cardiovascular Devices Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Drug Eluting Cardiovascular Devices Markets in 2024
10.2 Asia Pacific Drug Eluting Cardiovascular Devices Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Drug Eluting Cardiovascular Devices Market size Outlook by Segments, 2021-2030
By Product
Drug-Eluting Stents
Bioabsorbable Stents
Drug-Eluting Balloons
By End-User
Hospitals
Clinics
Others

11 South America Drug Eluting Cardiovascular Devices Market Analysis And Outlook To 2030
11.1 Introduction to South America Drug Eluting Cardiovascular Devices Markets in 2024
11.2 South America Drug Eluting Cardiovascular Devices Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Drug Eluting Cardiovascular Devices Market size Outlook by Segments, 2021-2030
By Product
Drug-Eluting Stents
Bioabsorbable Stents
Drug-Eluting Balloons
By End-User
Hospitals
Clinics
Others

12 Middle East And Africa Drug Eluting Cardiovascular Devices Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Drug Eluting Cardiovascular Devices Markets in 2024
12.2 Middle East and Africa Drug Eluting Cardiovascular Devices Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Drug Eluting Cardiovascular Devices Market size Outlook by Segments, 2021-2030
By Product
Drug-Eluting Stents
Bioabsorbable Stents
Drug-Eluting Balloons
By End-User
Hospitals
Clinics
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott
B. Braun Melsungen AG
Biotronik
Boston Scientific Corp
Cook Medical
Cordis Corp
Medtronic
MicroPort Scientific Corp
Sahajanand Medical Technologies
Terumo Corp

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Product
Drug-Eluting Stents
Bioabsorbable Stents
Drug-Eluting Balloons
By End-User
Hospitals
Clinics
Others